|
03 Dec 2021 |
Phase III trial with Nubeqa™ (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
|
|
03 Dec 2021 |
Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML
|
|
03 Dec 2021 |
Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001
|
|
03 Dec 2021 |
SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline
|
|
02 Dec 2021 |
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
|
|
02 Dec 2021 |
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
|
|
02 Dec 2021 |
Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG
|
|
02 Dec 2021 |
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
|
|
02 Dec 2021 |
ITM and Navigo Proteins Announce Research Collaboration to Develop FAP-targeting Radionuclide Therapy to Address Solid Tumors
|
|
02 Dec 2021 |
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
|
|
02 Dec 2021 |
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China
|
|
02 Dec 2021 |
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease
|
|
02 Dec 2021 |
Accutar Biotechnology Announces First Patient Dosed with AC0682 in Phase 1 Study in Patients with ER-Positive / HER2-Negative Locally Advanced or Metastatic Breast Cancer
|
|
02 Dec 2021 |
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
|
|
02 Dec 2021 |
LintonPharm Announces First Patient Dosed in Phase 1 Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
|
|
02 Dec 2021 |
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
|
|
02 Dec 2021 |
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
|
|
02 Dec 2021 |
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals
|
|
02 Dec 2021 |
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
|
|
02 Dec 2021 |
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
|
